ストックスクリーナーアプリを入手
4.01
11.48%
-0.52
アフターアワーズ：
3.83
-0.18
-4.49%
前日終値:
$4.53
開ける：
$4.5
24時間の取引高:
226.75K
Relative Volume:
1.35
時価総額：
$36.22M
収益：
$170.00K
当期純損益:
$-16.59M
株価収益率:
-2.098
EPS:
-1.9113
ネットキャッシュフロー:
$-15.98M
1週間 パフォーマンス:
-19.80%
1か月 パフォーマンス:
-20.28%
6か月 パフォーマンス:
+65.02%
1年 パフォーマンス:
+84.79%
1日の値動き範囲:
$3.675
$4.65
1週間の範囲:
$3.675
$5.02
52週間の値動き範囲:
$1.81
$5.07
Lisata Therapeutics Inc Stock (LSTA) Company Profile
Compare LSTA vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LSTA
Lisata Therapeutics Inc
|
4.01 | 40.92M | 170.00K | -16.59M | -15.98M | -1.9113 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lisata Therapeutics Inc (LSTA) 最新ニュース
Lisata Therapeutics extends deadline for Kuva tender offer - TipRanks
Financing delays put Lisata Therapeutics (LSTA) tender offer by Kuva Labs in doubt - Stock Titan
Lisata Therapeutics to be acquired by Kuva Labs in $4.00-per-share cash deal - MSN
Q2 2025 Lisata Therapeutics Inc Earnings Call Transcript - GuruFocus
Q3 2025 Lisata Therapeutics Inc Earnings Call Transcript - GuruFocus
LSTA Should I Buy - Intellectia AI
Lisata Therapeutics and Kuva Labs extend tender offer deadline to April 13 - Investing.com Australia
Lisata Therapeutics (LSTA) and Kuva Labs delay tender offer launch to April 13 - Stock Titan
Atlantic International Corp. and its subsidiary Lyneer officially filed a lawsuit with a New York court on April 1, accusing Spp Credit Advisors of misconduct. - bitget.com
According to the latest filing submitted to the U.S. Securities and Exchange Commission (SEC), biopharmaceutical company Lisata Therapeutics Inc (hereinafter referred to as "Lisata Therapeutics") and its partner Kuva Labs have jointly decided to officially ext - Bitget
Lisata Therapeutics Delays Tender Offer Launch in Merger - TipRanks
Lisata extends commencement date for tender offer under merger agreement to April 13 - TradingView — Track All Markets
Earnings Update: Is Lisata Therapeutics Inc stock technically oversold2026 Drop Watch & Stock Timing and Entry Methods - baoquankhu1.vn
Options Flow: Is Lisata Therapeutics Inc affected by consumer sentiment2026 Drop Watch & Smart Investment Allocation Insights - baoquankhu1.vn
Forecast Cut: What is Lisata Therapeutics Incs market positionInflation Watch & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Lisata Therapeutics Hits New 52-Week High of $5.06 - Markets Mojo
Lisata Therapeutics Q2 2025 Earnings Preview - MSN
Lisata Therapeutics agrees to $5 per share acquisition by Kuva Labs - Investing.com Nigeria
Lisata Therapeutics : Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K) - marketscreener.com
Lisata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Lisata Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Why Lisata Therapeutics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Sahm
Lisata Therapeutics to Be Acquired by Kuva Labs for $5.00 Per Share Plus Potential $1.00 CVR in 2026 Merger Deal - Minichart
Market movers: Hims & Hers, Lisata Therapeutics, Live Nation Entertainment... - Proactive financial news
Lisata Therapeutics shares up 20% as Kuva Labs acquisition advances - Yahoo Finance
Lisata Therapeutics to Be Acquired by Kuva Labs - TipRanks
Lisata Therapeutics to Be Acquired by Kuva Labs in $5.00-Per-Share Tender Offer Plus $1.00 CVR - TradingView
Kuva Labs to acquire Lisata (Nasdaq: LSTA) for $5.00 cash plus CVR - Stock Titan
Shareholder Alert: The Ademi Firm investigates whether Lisata Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders - PR Newswire
Lisata Therapeutics Agrees To Be Taken Private By Kuva Labs - Nasdaq
Lisata Therapeutics surges on Kuva Labs takeover proposal carrying hefty premium - MSN
Lisata Therapeutics (LSTA) to be Acquired by Kuva Labs in $5.00 per Share Deal - GuruFocus
Lisata Therapeutics Enters Into Definitive Agreement To Be Acquired By Kuva Labs, Inc. - TradingView
Lisata Therapeutics Announces Acquisition by Kuva Labs Inc. with $5.00 Cash Offer per Share - Quiver Quantitative
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc. - GlobeNewswire
Lisata Extends Kuva Labs Acquisition Term Sheet Timeline - The Globe and Mail
Lisata Extends Kuva Tender Offer Term Sheet to March 7 as Acquisition Talks Continue - TradingView
Will Lisata Therapeutics Inc. stock go up in YEARJuly 2025 Analyst Calls & Technical Pattern Based Buy Signals - mfd.ru
LSTA SEC FilingsLisata Therapeutics Inc 10-K, 10-Q, 8-K Forms - stocktitan.net
Lisata Therapeutics (LSTA) Price Target Increased by 19.30% to 11.56 - Nasdaq
LSTA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Why is Lisata Therapeutics Inc. stock going downAnalyst Downgrade & Precise Entry and Exit Recommendations - mfd.ru
What is the long term forecast for Lisata Therapeutics Inc. stockJuly 2025 Decliners & Comprehensive Market Scan Insights - mfd.ru
Can Lisata Therapeutics Inc. keep up with sector leadersTrade Risk Summary & Free Accurate Trade Setup Notifications - mfd.ru
LSTA PE Ratio & Valuation, Is LSTA Overvalued - Intellectia AI
Will Lisata Therapeutics Inc. (8NE) stock benefit from sector leadershipMarket Risk Summary & Accurate Intraday Trade Tips - mfd.ru
Are RAPT, ALGT, LSTA, AVO Obtaining Fair Deals for their Shareho - GuruFocus
Lisata Therapeutics Inc (LSTA) 財務データ
収益
当期純利益
現金流量
EPS
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):